Green tea extract tested to fight frailty in older cancer survivors

NCT ID NCT06068543

Terminated Symptom relief Sponsor: University of Rochester Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended, so results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Epigallocatechin-3-Gallate (EGCG), a green tea extract
What this could lead to: If it works, this could point toward a simple supplement to help older cancer survivors become less frail and feel stronger.
What could go wrong: This is a small, early-phase trial that is currently suspended. EGCG may not improve frailty, and high doses can cause liver issues in some people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Frailty Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FRAILTY INFLAMMATION

Contacts and locations

Locations

University of Rochester

Rochester, New York, 14627, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.